Autopsy report · NCT05778877

A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA

“Decided by sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

Selecta Biosciences, Inc.

Sponsor type

Industry

Conditions

Methylmalonic Acidemia (MMA)

Interventions

SEL-302

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Single Ascending Dose Trial in Patients With Type 2 Diabetes
  “Decision by Sponsor” (90% match in meaning)
• Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
  “Sponsor Decision” (88% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.